Astellas’ Tadaaki Taniguchi on how to challenge the status quo - European Medical Journal

Astellas’ Tadaaki Taniguchi on how to challenge the status quo

EMJ GOLD
Series 7: Episode 10

In this season finale of the EMJ GOLD podcast, Isabel speaks to Dr Tadaaki Taniguchi, Chief Medical Officer, Head of Medical and Development, Astellas Pharma, about how he strives to challenge the status quo in the pharmaceutical industry. 

The two discuss how Tadaaki’s time as a surgical oncologist has influenced his leadership style, how collaboration is key for making impacts for patients, the next game changers in cancer treatment and more.

A little bit more on EMJ GOLD’s guest… 

Dr Tadaaki Taniguchi leads Astellas’ global team in identifying, discovering and developing new treatments that have the potential to transform healthcare, with a focus on innovative and patient-centred therapies.

He has more than 20 years of industry experience spanning research, development and medical affairs, and has worked in a range of therapeutic areas including diabetes and oncology. Prior to joining Astellas, Tadaaki held senior positions at other major pharmaceutical companies in the US, Japan and China. Before joining the industry, he spent 10 years as a surgical oncologist – giving him a unique perspective on how to deliver breakthrough science that changes the way diseases are treated.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.